TransMedics Group, Inc. (TMDX) Total Return:-36.48%(TTM)
Over the latest trailing 12-month period, TransMedics Group, Inc. (TMDX)'s total return cagr is -36.48%. The comparable SPY value is +26.75%. Year-to-date total return is -35.23%. Total return includes price appreciation and reinvested dividends.
Growth of $10,000 in TMDX
$35,237
(3.5x return)
Invested on May 2, 2019
Growth of $10,000 in SPY (S&P 500)
$28,864
(2.9x return)
Invested on May 2, 2019
Hypothetical Growth of $10,000
This chart illustrates the cumulative performance of a hypothetical $10,000 investment. It assumes that all dividends paid by both the stock and SPY are reinvested in additional shares on the payment date, showing the true long-term compounding impact of distributions.
Recent Performance Indicators
YTD Total Return
-35.2%
1-Year Total Return
-36.5%
Current Dividend Yield
0.00%
Price CAGR vs. Total Return CAGR
Compound Annual Growth Rate (CAGR) is shown below. The difference between price CAGR and total return CAGR is the compound contribution of dividends reinvested.
| Holding Period | Price CAGR | Total Return CAGR | Dividend Addition |
|---|---|---|---|
| 1 Year | (36.5%) | (36.5%) | — |
| 3 Years | +0.1% | +0.1% | — |
| 5 Years | +21.5% | +21.5% | — |
| 10 Years | — | — | — |
| 15 Years | — | — | — |
| 20 Years | — | — | — |
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein